PerkinElmer Inc. Stock
PerkinElmer Inc. Stock
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the PerkinElmer Inc. stock is not clear.
On the other hand, the target price of €110.00 is below the current price of €120.00 for PerkinElmer Inc., so the potential is actually -8.333%.
So far the community has only identified positive things for PerkinElmer Inc. stock. The most positive votes were given for criterium "EBIT growth".
Pros and Cons of PerkinElmer Inc. in the next few years
Pros
Cons
Performance of PerkinElmer Inc. vs. its peers
| Security | Change (%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| PerkinElmer Inc. | -0.830% | -2.419% | 5.217% | 32.967% | 5.217% | 84.733% | 172.430% |
| Hologic Inc. | 0.000% | -2.381% | 0.000% | 25.510% | 6.957% | 77.746% | 90.520% |
| Boston Scientific | -0.890% | 0.635% | 6.793% | -23.153% | 2.818% | 32.039% | 83.310% |
| Thermo Fisher Scientific Inc. | 0.660% | -0.263% | 11.027% | 37.944% | 9.656% | 137.131% | 233.453% |
Comments
Other discussions about PerkinElmer Inc. Stock
Trading PerkinElmer Inc.
Trading PerkinElmer Inc.
News
PerkinElmer SARS-CoV-2 RT-PCR Assay Receives FDA EUA for Asymptomatic Testing
PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration
PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 2, 2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 66% and 63%
PerkinElmer to Acquire Oxford Immunotec Global PLC
PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms
PerkinElmer to Present at J.P. Morgan Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual J.P. Morgan Healthcare Conference on
PerkinElmer to Host Virtual Life Science Event
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will host a Virtual Life Science Event for the investment community on
PerkinElmer SARS-CoV-2 RT-PCR Assay Receives CE Mark for Saliva and Sample Pooling to Test Symptomatic and Asymptomatic Individuals
PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® SARS-CoV-2 Real-time RT-PCR Assay received CE-IVD marking for the use of saliva as specimen type and the option to pool up to five
EUROIMMUN Launches Quantitative ELISA to Measure SARS-CoV-2 Antibodies Against Viral S1 Protein
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM
PerkinElmer to Present at Wolfe Virtual Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Wolfe Virtual Healthcare Conference on Thursday
PerkinElmer to Present at Stifel Virtual Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Tuesday
PerkinElmer COVID-19 Test Kit Receives FDA Emergency Use Authorization for Sample Pooling
PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to allow sample pooling with PerkinElmer® New Coronavirus
PerkinElmer Announces Financial Results for the Third Quarter of 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 4, 2020.
The Company reported
PerkinElmer Receives CE Mark for Multi-analyte Respiratory Panel Including COVID-19
PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnostic (IVD) device in more than 30
PerkinElmer Board Declares Quarterly Dividend
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock October 22, 2020. This dividend is payable on February 12, 2021 to
CORRECTING and REPLACING PerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday, October 28, 2020
The table in the release was incorrect. The corrected table should read:
PerkinElmer, Inc:
PerkinElmer, Inc. and SubsidiariesRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
PerkinElmer to Present at BofA Global Healthcare Conference 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the BofA Global Healthcare Conference 2020 on
